Pegylated Interferon - α2b With SARSCoV- 2 (COVID-19)

Summary

This is a phase II, multicenter, open-label, randomized, comparator-controlled study to evaluate the efficacy and safety of Pegylated Interferon -α2b in the treatment of adult patients diagnosed with SARS-CoV2 (COVID-19).Initial 1 mcg/kg of Pegylated Interferon-α2b will be administered on day 1. After safety evaluation of first dose, next dose (second dose) 1 mcg/kg on day 8 will be administered with recommended standard care during the trial.

Timeline

Start

2020-08-11

Primary completion

2021-06-21

Completion

2021-06-21

Drugs

Indications